LON:MTPH Biodexa Pharmaceuticals (MTPH) Share Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free MTPH Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 18▼ 1852-Week Range N/AVolume73,672 shsAverage Volume617,252 shsMarket Capitalization£31.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biodexa Pharmaceuticals alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Biodexa Pharmaceuticals Stock (LON:MTPH)Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. MTPH Stock News HeadlinesApril 26, 2024 | seekingalpha.comBiodexa shares rally 126% on rapamycin licensing dealApril 25, 2024 | americanbankingnews.comBiodexa Pharmaceuticals (LON:MTPH) Stock Price Passes Above 50-Day Moving Average of $18.00April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 16, 2024 | americanbankingnews.comBiodexa Pharmaceuticals (LON:MTPH) Stock Crosses Below Fifty Day Moving Average of $18.00March 28, 2024 | seekingalpha.comSLRX Salarius Pharmaceuticals, Inc.February 23, 2024 | msn.comBiodexa stock slides 7% amid data for two drug studiesFebruary 8, 2024 | markets.businessinsider.comBiodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsFebruary 7, 2024 | msn.comBiodexa stock jumps on allowance of U.S. patent covering TolimidoneApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.February 7, 2024 | tmcnet.comBiodexa Announces Allowance of U.S. Patent Covering TolimidoneDecember 19, 2023 | msn.comBiodexa Pharmaceuticals down 21%, prices equity offeringNovember 28, 2023 | msn.comWhat's Going On With Biodexa Pharmaceuticals Stock (BDRX) Today?November 27, 2023 | marketwatch.comBiodexa Enters Worldwide Licensing Deal for TolimidoneNovember 27, 2023 | msn.comBiodexa jumps on licensing deal for diabetes candidateNovember 27, 2023 | marketwatch.comBiodexa Pharma Shares Double After Licensing Deal for TolimidoneNovember 19, 2023 | morningstar.comBiodexa Pharmaceuticals Plc ADR BDRXOctober 3, 2023 | tmcnet.comBiodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaJune 23, 2023 | msn.comBiodexa Pharmaceuticals announces ADR ratio changeMay 18, 2023 | technews.tmcnet.comBiodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian BiopharmaceuticalsApril 22, 2023 | investing.comBiodexa Pharmaceuticals PLC DRC (BDRX)April 3, 2023 | finance.yahoo.comBiodexa Pharmaceuticals PLC Announces Issue of Pre-Funded WarrantsMarch 28, 2023 | finance.yahoo.comBiodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of EquityMarch 27, 2023 | finance.yahoo.comMidatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal DiseaseMarch 24, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Results of General MeetingMarch 10, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Further re: Notice of General MeetingFebruary 15, 2023 | finance.yahoo.comMidatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker ChangeFebruary 9, 2023 | marketwatch.comMidatech Pharma to Raise About $6 Million to Develop Cancer TreatmentSee More Headlines Receive MTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/10/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:MTPH CUSIPN/A CIKN/A Webwww.midatechpharma.com Phone+44-1235-841575FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.47% Return on Assets-52.50% Debt Debt-to-Equity Ratio9.52 Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales£645,000.00 Price / Sales48.38 Cash FlowGBX 20.53 per share Price / Cash Flow0.88 Book ValueGBX 152 per share Price / Book0.12Miscellaneous Outstanding Shares173,350,000Free FloatN/AMarket Cap£31.20 million OptionableNot Optionable Beta1.22 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Stephen A. Stamp (Age 61)CEO, CFO, Company Sec. & Director Comp: $233.87kDr. Dmitry Zamoryakhin M.D. (Age 43)Chief Scientific Officer Comp: $231.47kDr. Daniel Palmer MBAPh.D., VP of TechnologyDr. Tim Sparey Ph.D.Chief Bus. OfficerMr. Justin Barry BSc (Hons.)MBIOL, CBIOL, QP, Head of ManufacturingMr. Vincent HolmesVP & Head of Clinical OperationsMr. David Benharris (Age 58)Pres of Midatech Pharma US Inc Ms. Fiona SharpGroup Financial ControllerMore ExecutivesKey CompetitorsCollagen Solutions plc (COS.L)LON:COS4D pharmaLON:DDDDRedx PharmaLON:REDXOKYO PharmaLON:OKYOC4X DiscoveryLON:C4XDView All Competitors MTPH Stock Analysis - Frequently Asked Questions How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals Plc (LON:MTPH) released its quarterly earnings results on Thursday, September, 10th. The company reported ($64.00) EPS for the quarter. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include Aldeyra Therapeutics (ALDX), Barclays (BARC), Telefonaktiebolaget LM Ericsson (publ) (ERIC), Futura Medical (FUM), Lloyds Banking Group (LLOY), Biodexa Pharmaceuticals (MTP), Intec Pharma (NTEC), Pearson (PSON), Royal Mail (RMG) and AON (AON). How do I buy shares of Biodexa Pharmaceuticals? Shares of MTPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MTPH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.